Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole vs Amphotericin-B in Acute Invasive Aspergillosis
NCT00003031Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 1997
- Primary completion
- Oct 2000
- Modality
- Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of voriconazole in Acute Invasive Aspergillosis (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Efficacy of treatment at 12 weeks and Safety and toleration at 16 weeks. Started Jun 1997; status: completed.
02
Drugs
voriconazole
03
Conditions
Acute Invasive Aspergillosis
Beyond the preview
Go deeper on NCT00003031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003031.